MARLBOROUGH, Mass.,
May 27, 2014 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
focused on discovering, developing and commercializing innovative
therapies addressing major unmet medical needs using RNA-targeted
technologies, today announced that the Company's President
& CEO, Dr. Geert Cauwenbergh,
will present at the Jefferies 2014 Global Healthcare Conference on
Tuesday, June 3, 2014 at 8:00 a.m. EDT. Dr. Cauwenbergh will discuss
the development of RXI-109, a self-delivering RNAi compound
designed to reduce dermal scarring, as well as business development
opportunities with RXi's sd-rxRNA® technology platform.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
The presentation will be webcast and available on the
"Investors" section of the Company's website,
www.rxipharma.com.
About Jefferies 2014 Global Healthcare Conference
This conference will feature an extensive range of public and
private healthcare companies across the biopharmaceuticals, life
sciences, healthcare services, healthcare IT and medical technology
sectors, with over 300 participating companies and 2,500 attendees.
This global gathering of leading executives, institutional
investors, private equity investors and VCs will address near- and
long-term investment opportunities and discuss the mechanisms
driving healthcare in the U.S. and internationally. This conference
will take place June 2-5, 2014 in
New York City.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi platform. Therapeutics that use RNA
interference, or "RNAi," have great promise because of their
ability to down-regulate the expression of specific genes that may
be over-expressed in disease conditions. Building on the pioneering
work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the Company's
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, entered into human clinical trials in June 2012 and is currently in Phase 2. RXI-109
targets connective tissue growth factor (CTGF) to reduce dermal
scarring (fibrosis). For more information, please visit
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks and
uncertainties: the risk that we may not be able to
successfully develop our candidates, or that development of
RNAi-based therapeutics may be delayed or not proceed as planned,
or that we may not develop any RNAi-based products; risks that the
development process for our product candidates may be delayed,
risks related to the development and commercialization of products
by our competitors, the risk related to our ability to control the
timing and terms of collaborations with third parties, and the
possibility that other companies or organizations may assert patent
rights preventing us from developing our products. Actual results
may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation